Washington, D.C. 20549


FORM 12b-25





(Check one):         ☒ Form 10-K         ☐ Form 20-F         ☐ Form 11-K         ☐ Form 10-Q         ☐ Form 10-D         ☐ Form N-SAR         ☐ Form N-CSR

For Period Ended: December 31, 2021                      

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transition Period Ended:                                                                                               


Read Instruction (on back page) Before Preparing Form. Please Print or Type.


Nothing in this form shall be construed to imply that the Commission has veried any information contained herein.


If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:






Statera Biopharma, Inc.

Full Name of Registrant




Not Applicable

Former Name if Applicable


2537 Research Boulevard, Suite 201

Fort Collins, CO 80526

Address of Principal Executive Office (Street and Number)

City, State and Zip Code



PART II RULES 12b-25(b) AND (c)


If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)


(a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

(b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.






State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.


Statera Biopharma, Inc. (the “Registrant”) was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the period ended December 31, 2021 (the “Annual Report”) by the filing date applicable to smaller reporting companies due to a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. As a result, the Registrant is still in the process of compiling required information to complete the Annual Report and its independent registered public accounting firm requires additional time to complete its audit of the financial statements for the period ended December 31, 2021 to be included in the Annual Report. The Registrant anticipates that it will file the Annual Report no later than the fifteenth calendar day following the prescribed filing date.







Name and telephone number of person to contact in regard to this notification


Peter Aronstam   (888)   613-8802
(Name)   (Area Code)   (Telephone Number)




Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ☒     No ☐




Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☒     No ☐


If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.


The Registrant anticipates that, due to the completion of its previously disclosed merger with Cytocom Inc. (“Cytocom”) in July 2021 and the fact that the Company’s financial statements now reflect the historical results of Cytocom prior to the completion of the merger, and do not include the historical results of the Registrant prior to the completion of the merger, there will be a significant change in results of operations from the fiscal period ended December 31, 2020. These changes will be reflected by the statements of operations to be included in the subject report. The Company anticipates reporting significant changes in, among other things, its revenues, research and development expenses, sales and marketing expenses, other income and expense, in particular impairment loss, and general and administrative costs, but at this time cannot reasonably estimate the amount of these or other changes because the Company’s independent registered public accounting firm has not yet completed the audit of the Company’s financial statements.


Cautionary Note Regarding Forward-Looking Statements


This Form 12b-25 contains forward-looking statements that involve risks and uncertainties. Forward-looking statements give our current expectations of forecasts of future events. All statements other than statements of current or historical fact contained in this filing, including statements regarding our future financial position, business strategy, new products, budgets, liquidity, cash flows, projected costs, regulatory approvals or the impact of any laws or regulations applicable to us, and plans and objectives of management for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations about future events. While we believe these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond our control. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this filing are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.




Statera Biopharma, Inc.

(Name of Registrant as Specified in Charter)


has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.












 Date: March 31, 2022


/s/ Peter Aronstam




 Peter Aronstam, Chief Financial Officer